Meanwhile, the S&P BSE Sensex was up 87.43 points or 0.43% at 20,300.39
On BSE, 18,373 shares were traded in the counter as against average daily volume of 17,191 shares in the past one quarter.
The stock hit a high of Rs 2,142.25 and a low of Rs 2,075 so far during the day. The stock had hit record high of Rs 2,150.90 on Monday, 13 May 2013. The stock had hit a 52-week low of Rs 1,528 on 19 June 2012.
The stock had outperformed the market over the past one month till 15 May 2013, gaining 11.38% compared with the Sensex's 10.11% rise. The scrip had also outperformed the market in past one quarter, rising 13.56% as against Sensex's 3.83% gain.
The large-cap company has equity capital of Rs 84.91 crore. Face value per share is Rs 5.
Shares of Dr Reddy's Laboratories gained 1.92% to settle at Rs 2,064.55 on Wednesday, 15 May 2013. The stock had declined 2.65% to settle at Rs 2,025.65 on Tuesday, 14 May 2013 on profit booking after the company reported good Q4 results during trading hours on that day. Earlier, the stock had witnessed a pre-result rally. The stock had surged 10.44% to settle at Rs 2,080.95 on Monday, 13 May 2013, from a recent low of Rs 1,884.20 on 22 April 2013.
Dr Reddy's Laboratories' consolidated net profit surged 66.6% to Rs 570.89 crore on 25.6% growth in net sales to Rs 3339.94 crore in Q4 March 2013 over Q4 March 2012.
Dr Reddy's Laboratories' consolidated net profit rose 17.6% to Rs 1677.62 crore on 20.2% growth in net sales to Rs 11626.56 crore in the year ended 31 March 2013 (FY 2013) over the year ended 31 March 2012 (FY 2012).
Dr Reddy's Laboratories said that the revenue growth in FY 2013 was primarily driven by North America and Emerging markets (which include Russia, other CIS countries and Rest of World territories) in the Global Generics segment; and overall performance by Pharmaceutical Services and Active Ingredients segment.
During the year, the company benefited by an amount of $22.5 million from one-time settlement done with Nordion Inc (which is formerly MDS Inc). The settlement is towards the damages sustained by the company due to the breach by Nordion of the then existing laboratory services agreement for bioequivalence studies, Dr Reddy's Lab said in statement.
Dr Reddy's Laboratories' capital expenditure for FY 2013 was Rs 660 crore.
In Q4 March 2013, the company launched 18 new generic products, filed 14 new product registrations and filed 17 DMFs globally. In FY 2013, the company launched 78 new generic products, filed 56 new product registrations and filed 47 DMFs globally.
Dr Reddy's Laboratories' board of directors at its meeting held on 14 May 2013 recommended a final dividend of Rs 15 per share for the year ended 31 March 2013.
Dr Reddy's Laboratories is an integrated global pharmaceutical company. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - Dr Reddy's offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Major Therapeutic focus is on gastro-intestinal, cardiovascular, diabetology, oncology, pain management and anti-infective. Major markets include India, USA, Russia-CIS and Europe apart from other select geographies within emerging markets.
Powered by Capital Market - Live News
